arrow
H

Helmuth Haslacher

university hospital vienna
H指数:37
被引数:5,138

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Post-transplant ring sideroblasts are common in haploidentical peripheral blood stem cell transplantation but not linked to SF3B1 mutations

移植后环形铁粒幼细胞在单倍型外周血干细胞移植中常见,但与SF3B1突变无关

2026-07-240
PRE
Short- and long-term risk stratification in acutely ill medical patients by implementing D-dimer in the emergency setting - A prospective cohort study

急诊环境中通过D-二聚体实施对急性内科患者的短期和长期风险分层——一项前瞻性队列研究

2026-05-010
OA
Antibody development after three mRNA SARS-CoV-2 vaccinations in patients with systemic autoimmune rheumatic disease with and without treatment: an observational cohort study

三剂mRNA SARS-CoV-2疫苗接种后,系统性自身免疫性风湿病患者(接受治疗与未接受治疗者)的抗体发展情况:一项观察性队列研究

2025-09-231
OAAI
Clinical evidence for antiglycoprotein IIbIIIa antibody-induced platelet desialylation in primary immune thrombocytopenia

原发性免疫性血小板减少症患者中抗糖蛋白IIbIIIa抗体诱导血小板去唾液酸化的临床证据

2025-06-030
OAAI
Autoantibody development is associated with clinical severity of COVID-19: A cohort study

自身抗体发展与COVID-19临床严重程度相关:一项队列研究

2025-05-011
PRE
Short- and long-term risk stratification in acutely ill medical patients by implementing ankle-brachial index and pulse wave velocity in the emergency setting
2025-03-010
OAAI
Immunogenicity and safety of COVID-19 booster vaccination: A population-based clinical trial to identify the best vaccination strategy

新型冠状病毒肺炎加强疫苗接种的免疫原性和安全性: 一项基于人群的临床试验,以确定最佳的疫苗接种策略

2024-08-012
PRE
Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases

曲妥珠单抗-deruxtecan治疗活动性脑转移的HER2-positive乳腺癌患者的II期TUXEDO-1试验的最终结果分析

2024-07-048
OAAI
FINAL OUTCOME ANALYSIS FROM THE PHASE II TUXEDO-1 TRIAL OF TRASTUZUMAB-DERUXTECAN IN HER2-POSITIVE BREAST CANCER PATIENTS WITH ACTIVE BRAIN METASTASES
2024-05-020
PRE
Effect of monovalent COVID-19 vaccines on viral interference between SARS-CoV-2 and several DNA viruses in patients with long-COVID syndrome
2023-09-294
OAAI